NCT04464967 - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | Biotech Hunter

Timeline

Start Date

March 31, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

February 28, 2023

Conditions

Advanced Solid TumorMetastatic CancerHER2-positive Breast CancerHER2-positive Gastric CancerHER-2 Protein OverexpressionEsophageal CancerOvarian CancerEndometrium CancerBladder CancerPancreatic CancerColorectal CancerNon Small Cell Lung CancerEGF-R Positive Non-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaTriple Negative Breast CancerCervical CancerSarcoma

Interventions

BIOLOGICAL

SNK01

Patient-specific ex vivo expanded autologous natural killer cells

DRUG

Trastuzumab

HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody

DRUG

Cetuximab

EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody